Clinical trial
Docetaxel and Capecitabine in Advanced Gastric Cancer
NCT00142038 · Charite University, Berlin, Germany, Other · Completed
Key facts
| NCT number | NCT00142038 |
|---|---|
| Title | Docetaxel and Capecitabine in Advanced Gastric Cancer |
| Official title | Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomach Neoplasm, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Docetaxel, Capecitabine |
| Enrollment | 80 |
| Start date | Mar 1, 2004 |
| Completion | Dec 1, 2007 |
| First posted | Sep 2, 2005 |
| Last update posted | Apr 18, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: